# GLP-1s for $50 a Month? 14 Million Medicare Recipients May Be Eligible
Up to 14 million Medicare recipients now qualify for glucagon-like peptide-1 receptor agonists (GLP-1s) at a capped monthly cost of $50, a shift that dramatically expands access to drugs like semaglutide and tirzepatide for older Americans managing type 2 diabetes and obesity.
The $50 monthly cap represents a watershed moment for Medicare coverage. Previously, these medications—which suppress appetite and improve blood sugar control—carried costs that put them beyond reach for many seniors on fixed incomes. The new pricing applies to all GLP-1 medications covered under Medicare Part D, the prescription drug benefit program.
This eligibility expansion matters because GLP-1s have emerged as one of the most effective weight loss and diabetes management tools available. Research demonstrates these drugs help people lose 15 to 22 percent of their body weight when combined with lifestyle changes. For type 2 diabetes specifically, GLP-1s reduce cardiovascular risks beyond simple glucose control.
Medicare eligibility hinges on enrollment in Part D plans that include these medications, plus reaching an out-of-pocket spending threshold. Beneficiaries need to contact their specific Medicare plan to confirm coverage and confirm their personal GLP-1 qualifies. Some plans may cover multiple GLP-1 options, while others offer limited formularies.
The cost reduction acknowledges a persistent barrier: Americans often skip doses or abandon GLP-1 treatment entirely when insurance coverage lapses or copays climb above $250 monthly. For seniors already managing multiple chronic conditions, the $50 cap removes a financial barrier that previously forced difficult choices between medication and other essentials.
Eligible beneficiaries should review their current Medicare Part D plan documents or call 1-